Weight Loss3 mins read

Retatrutide vs. Ozempic: What Eli Lilly’s Head-to-Head Trial Found

Eli Lilly says retatrutide led to substantially more weight loss than Ozempic in a clinical trial of people with type 2 diabetes, while showing a broadly similar side-effect profile with some differences.

Can GLP-1s slow down aging? Eli Lilly and Novo Nordisk are testing the idea.

The headline result: more weight loss than Ozempic

Eli Lilly announced results from the first clinical trial directly comparing Ozempic with retatrutide, its still-investigational injectable drug for obesity and diabetes. In people with type 2 diabetes, patients on the highest dose of Ozempic lost an average of 21 pounds over about a year and a half, while those on retatrutide lost an average of 44 pounds at 9 mg to 47 pounds at 12 mg. Retatrutide also showed steeper reductions in A1C, a key blood-sugar marker, at 2.2% versus 1.8%.

Why retatrutide is being watched closely

ozempic pen
Image credits:Svitlana Pietukhova/Getty Images

Ozempic mimics one gut hormone, GLP-1, while Eli Lilly’s Mounjaro mimics GLP-1 and GIP. Retatrutide goes further by mimicking three hormones: GLP-1, GIP, and glucagon, which helps break down stored fat into energy. That triple-hormone design is why insiders have called it “triple G” and “King Kong” for weight loss.

Approval is still ahead, not here yet

Retatrutide is still in clinical development and has not been approved by the FDA or any regulatory organization. Business Insider reported that Eli Lilly is expected to submit the drug to the US Food and Drug Administration in early 2027. If approved, it could be used for conditions including obesity, obesity-related sleep apnea, and knee osteoarthritis.

Side effects and safety caveats matter

The trial’s side-effect profiles were generally similar between Ozempic and retatrutide, but with differences. More retatrutide patients reported diarrhea, while constipation was slightly more common among Ozempic users; retatrutide patients also had slightly higher rates of dysesthesia, a rare tingling or skin-on-fire sensation. The results have not yet been peer-reviewed or published in a medical journal.

The black-market warning

Retatrutide’s pre-approval buzz has already fueled copycat peptide sales labeled “reta,” including powders shipped from overseas for do-it-yourself injections. Eli Lilly warned that retatrutide remains investigational and said anyone purporting to sell it to consumers is breaking the law. The practical takeaway: the drug may be promising, but unsanctioned versions carry major uncertainty about what buyers are actually taking.